IFFIFF exhibits solid fundamental strength and a positive outlook driven by its diverse product portfolio. While current technicals indicate some short-term weakness, the long-term growth potential and stable dividend make it an attractive option for growth and income investors.
International Flavors & Fragrances (IFF) operates in several growing segments including health, biosciences, and consumer products, benefiting from trends in natural ingredients, functional foods, and sustainable sourcing. Expansion into emerging markets and a focus on innovation contribute to its thematic appeal.
IFF demonstrates a solid financial foundation with consistent revenue generation and a manageable debt level. Recent quarterly results have shown an improvement in net income after a period of losses, indicating a positive turn. The dividend yield provides an income component for investors.
The stock is trading below its 50-day and 200-day moving averages, suggesting a prevailing bearish or consolidation trend. Oscillators like RSI and MACD are mixed, indicating a lack of strong momentum in either direction.
| Factor | Score |
|---|---|
| Health & Wellness Trends | 85 |
| Sustainability & Natural Ingredients | 80 |
| Emerging Markets Growth | 70 |
| Product Diversification | 75 |
| Regulatory Landscape | 65 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 30 |
| Growth | 40 |
| Balance Sheet Health | 80 |
| Cash Flow | 75 |
| Dividends | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 50 |
| Volume Analysis | 70 |
| Support & Resistance | 70 |
| MACD Indicator | 50 |
Positive EPS Surprises
The company has a track record of exceeding EPS estimates, with positive surprises in 10 out of the last 12 reported quarters. The most recent quarter (2025 Q2) showed a surprise of 5.29% (reported $1.20 vs. estimate $1.14).
Improving Debt-to-Equity Ratio
The Debt-to-Equity ratio has shown a declining trend, from 1.3 in 2022Q4 to 0.8 in 2024Q4. This indicates a strengthening balance sheet and reduced financial risk.
Missed EPS Estimates
The company missed the EPS estimate in the most recent quarter (2024Q4), reporting $0.72 against an estimate of $0.75, indicating potential operational challenges.
High P/E Ratio on Reported Earnings
The trailing P/E ratio is -19.3 due to recent net losses. The forward P/E (based on estimated earnings for 2025) is not directly available in the provided data, but the historical P/E ratios in 2021 (130.3) and 2024 (88.1) indicate periods of high valuation.
June 2025
20
Ex-Dividend Date
July 2025
11
Next Dividend Date
August 2025
6
Next Earnings Date
H: $1.15
A: $1.12
L: $1.10
H: 2.78B
A: 2.70B
L: 2.62B
International Flavors & Fragrances Inc., together with its subsidiaries, manufactures and markets food, beverage, health and biosciences, scent, pharma solutions, and complementary adjacent products in the United States, Europe, and internationally. It operates in four segments Nourish, Health & Biosciences, Scent, and Pharma Solutions. The Nourish segment consists of portfolio of natural-based ingredients that includes plant-based specialty food ingredients, such as soy and pea protein with value-added formulations, emulsifiers, and sweeteners; food protection ingredients, including natural antioxidants, and anti-microbials for natural food preservation and shelf-life extension; savory solutions, such as spices, marinades, and mixtures; combining flavourings with fruits, vegetables, and other natural ingredients products; a range of flavor compounds used in savory products, such as soups, sauces, meat, fish, poultry, and snacks; and beverages juice drinks, carbonated or flavored beverages, and spirits, as well as sweets bakery products, candy, cereal, and chewing gum; and dairy products, such as yogurt, ice cream, and cheese, as well as spices and seasoning ingredients. Its Health & Biosciences is comprised of health, cultures and food enzymes, home and personal care, animal nutrition, and grain processing. The Scent segment creates fragrance compounds, and fragrance ingredients. Its Pharma Solutions segment produces cellulosics and seaweed-based pharmaceutical excipients. The company was incorporated in 1909 and is headquartered in New York, New York.
91.29 USD
The 39 analysts offering 1 year price forecasts for IFF have a max estimate of 110.11 and a min estimate of 73.00.